Picture of a sphere with binary code

Making Strathclyde research discoverable to the world...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs. It exposes Strathclyde's world leading Open Access research to many of the world's leading resource discovery tools, and from there onto the screens of researchers around the world.

Explore Strathclyde Open Access research content

Essential role for proteinase-activated receptor-2 in arthritis

Ferrell, W.R. and Lockhart, J.C. and Kelso, E.B. and Dunning, L. and Plevin, R.J. and Meek, S.E. and Smith, A.J. and Hunter, G.D. and McLean, J.S. and McGarry, F. and Ramage, R. and Jiang, L. and Kanke, T. and Kawagoe, J. (2003) Essential role for proteinase-activated receptor-2 in arthritis. Journal of Clinical Investigation, 111 (1). pp. 35-41. ISSN 0021-9738

[img]
Preview
PDF (jci.pdf)
jci.pdf

Download (1MB) | Preview

Abstract

Using physiological, pharmacological, and gene disruption approaches, we demonstrate that proteinase-activated receptor-2 (PAR-2) plays a pivotal role in mediating chronic inflammation. Using an adjuvant monoarthritis model of chronic inflammation, joint swelling was substantially inhibited in PAR-2-deficient mice, being reduced by more than fourfold compared with wild-type mice, with virtually no histological evidence of joint damage. Mice heterozygous for PAR-2 gene disruption showed an intermediate phenotype. PAR-2 expression, normally limited to endothelial cells in small arterioles, was substantially upregulated 2 weeks after induction of inflammation, both in synovium and in other periarticular tissues. PAR-2 agonists showed potent proinflammatory effects as intra-articular injection of ASKH95, a novel synthetic PAR-2 agonist, induced prolonged joint swelling and synovial hyperemia. Given the absence of the chronic inflammatory response in the PAR-2-deficient mice, our findings demonstrate a key role for PAR-2 in mediating chronic inflammation, thereby identifying a novel and important therapeutic target for the management of chronic inflammatory diseases such as rheumatoid arthritis.